Biotech Co. Inflated Gene Therapy Prospects, Investors Claim

By Rui Johnson Petri · March 29, 2024, 12:52 PM EDT

Massachusetts-based biotechnology company Bluebird Bio Inc. misled investors by understating the safety concerns of a gene therapy for sickle cell, causing damages when stock prices dropped, according to a proposed class...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Related Sections

Case Information

Case Title

Gill v. bluebird bio, Inc. et al

Case Number

1:24-cv-10803

Court

Massachusetts

Nature of Suit

Securities/Commodities

Date Filed

March 28, 2024

Featured Stories

This Week's Healthcare Earnings: UnitedHealth, HCA, J&J No Photo Available

Yeji Jesse Lee

It was a week of good news and bad news for the healthcare industry. Earnings season kicked off when three companies posted financials... (more story)

Texas AG's Vaccine Probe Draws Fire From Health Experts No Photo Available

Hannah Albarazi

Public health experts are condemning a Texas Attorney General inquiry into Pfizer, UnitedHealth Group and others for allegedly tapping... (more story)

Biotech Fundraising A Good Sign For Public Markets No Photo Available

Yeji Jesse Lee

At the start of what many healthcare attorneys hope will be a busy year, public biotechs are raising cash, signaling a thawing public ... (more story)